NCT06239480Phase 3Active not recruiting

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Study sponsor: Palvella Therapeutics, Inc. · PVLA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01-14Actual

Enrollment · participants51Actual

Source updated2026-03-27Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-27 · 5 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~40 participants (planned)~~

+ After

51 participants (actual)

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Jan 2026~~

+ After

14 Jan 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source